SCHEMBL14866202

SCHEMBL14866202

COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1nc(Nc2ccccc2S(=O)(=O)C(C)C)c2ccccc2n1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 17/20 0.85
▸ INSR P06213 5/20 0.78
▸ IGF1R P08069 5/20 0.78
▸ FES P07332 3/20 0.78
▸ FLT3 P36888 3/20 0.78
▸ PTK2 Q05397 3/20 0.78
▸ PTK2B Q14289 3/20 0.78
▸ TTK P33981 3/20 0.78
▸ BMPR1B O00238 2/20 0.78
▸ PLK4 O00444 2/20 0.78
▸ GAK O14976 2/20 0.78
▸ ERN1 O75460 2/20 0.78
▸ STK10 O94804 2/20 0.78
▸ ABL1 P00519 2/20 0.78
▸ EGFR P00533 2/20 0.78
▸ LCK P06239 2/20 0.78
▸ FYN P06241 2/20 0.78
▸ YES1 P07947 2/20 0.78
▸ HCK P08631 2/20 0.78
▸ ROS1 P08922 2/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14866161 0.97 ALK (0.83) ALKINSRIGF1RFESFLT3
SCHEMBL14866525 0.95 ALK (0.89) ALKINSRIGF1RFESFLT3
SCHEMBL14866413 0.94 ALK (0.88) ALKINSRIGF1RFESFLT3
SCHEMBL14866415 0.94 ALK (0.88) ALKINSRIGF1RFESFLT3
SCHEMBL14866148 0.94 ALK (0.77) ALKINSRIGF1RFESFLT3
SCHEMBL14866453 0.94 ALK (0.75) ALKINSRIGF1RFESFLT3
SCHEMBL14866423 0.93 ALK (0.84) ALKINSRIGF1RFESFLT3
SCHEMBL14866516 0.93 ALK (0.86) ALKINSRIGF1RFESFLT3
SCHEMBL14866155 0.93 ALK (0.74) ALKINSRIGF1RFESFLT3
SCHEMBL14866421 0.93 ALK (0.74) ALKINSRIGF1RFESFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096100-A1 DI(ARYLAMINO)ARYL COMPOUND ASTELLAS PHARMA INC. (JP) 2013-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096100-A1 DI(ARYLAMINO)ARYL COMPOUND ERBB4, EGFR, ALK ALK 3/4885INSR 607/4885IGF1R 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback